Literature DB >> 21813762

The early history of tumor virology: Rous, RIF, and RAV.

Harry Rubin1.   

Abstract

One hundred years ago Peyton Rous recovered a virus, now known as the Rous sarcoma virus (RSV), from a chicken sarcoma, which reproduced all aspects of the tumor on injection into closely related chickens. There followed recovery of causal viruses of tumors of different morphology from 4 more of 60 chicken tumors. Subsequent studies in chickens of the biology of the first RSV isolated moved slowly for 45 y until an assay of ectodermal pocks of the chorioallantoic membrane of chicken embryos was introduced. The inadequacies of that assay were resolved with the production of transformed foci in cultures of chicken fibroblasts. There followed a productive period on the dynamics of RSV infection. An avian leukosis virus (ALV) was found in some chicken embryos and named resistance-inducing factor (RIF) because it interferes with RSV. Its epidemiology in chickens is described. Another ALV was found in stocks of RSV and called Rous-associated virus (RAV). Cells preinfected with RAV interfere with RSV infection, but RSV does not produce infectious virus unless RAV is added during or after RSV infection. Intracellular RAV provides the infectious coat for the otherwise defective RSV. The coat determines the antigenicity, host range, and maturation rate of RSV. RSV particles carry reverse transcriptase, an enzyme that converts their RNA into DNA and allows integration into the cell's DNA, where it functions as a cellular gene. This was the bridge that joined the biological era to the molecular era. Its relation to oncogenes and human cancer is discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21813762      PMCID: PMC3167550          DOI: 10.1073/pnas.1108655108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  95 in total

1.  Separation of morphological conversion and virus production in Rous sarcoma virus infection.

Authors:  H M TEMIN
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1962

2.  Virus of avian myeloblastosis. XIV. Neoplastic response of normal chicken bone marrow treated with the virus in tissue culture.

Authors:  G S BEAUDREAU; C BECKER; R A BONAR; A M WALLBANK; D BEARD; J W BEARD
Journal:  J Natl Cancer Inst       Date:  1960-02       Impact factor: 13.506

3.  Quantitative studies on Rous sarcoma virus. IV. An investigation of the nature of "noninfective" tumors induced by low doses of virus.

Authors:  A M PRINCE
Journal:  J Natl Cancer Inst       Date:  1959-12       Impact factor: 13.506

4.  An analysis of the assay of Rous sarcoma cells in vitro by the infective center technique.

Authors:  H RUBIN
Journal:  Virology       Date:  1960-01       Impact factor: 3.616

5.  A cell-associated factor essential for formation of an infectious form of Rous sarcoma virus.

Authors:  H Hanafusa; T Miyamoto; T Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1970-06       Impact factor: 11.205

6.  RNA-dependent DNA polymerase in virions of RNA tumour viruses.

Authors:  D Baltimore
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

7.  RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

Authors:  H M Temin; S Mizutani
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

8.  The murine leukemia-sarcoma virus complex.

Authors:  R J Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

9.  A virus released by "nonproducing" Rous sarcoma cells.

Authors:  P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

10.  Quantitative studies on the latent period of tumors induced with subcutaneous injections of the agent of chicken tumor I; curve relating dosage of agent and chicken response.

Authors:  W R BRYAN
Journal:  J Natl Cancer Inst       Date:  1946-02       Impact factor: 13.506

View more
  10 in total

1.  Molecular events accompanying rous sarcoma virus rescue from rodent cells and the role of viral gene complementation.

Authors:  Anna Lounková; Eduarda Dráberová; Filip Šenigl; Katerina Trejbalová; Josef Geryk; Jirí Hejnar; Jan Svoboda
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

2.  Retroviral host range extension is coupled with Env-activating mutations resulting in receptor-independent entry.

Authors:  Anna Lounková; Jan Kosla; David Přikryl; Kryštof Štafl; Dana Kučerová; Jan Svoboda
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

3.  On board a raft or boat in the retrovirus sea.

Authors:  Jan Svoboda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-30       Impact factor: 11.205

4.  The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique.

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  J Biosci       Date:  2013-09       Impact factor: 1.826

5.  The molecular biology of soft-tissue sarcomas and current trends in therapy.

Authors:  Jorge Quesada; Robert Amato
Journal:  Sarcoma       Date:  2012-05-10

Review 6.  Kirsten Ras* oncogene: significance of its discovery in human cancer research.

Authors:  Nobuo Tsuchida; Avaniyapuram Kannan Murugan; Michele Grieco
Journal:  Oncotarget       Date:  2016-07-19

7.  The full recovery of mice (Mus Musculus C57BL/6 strain) from virus-induced sarcoma after treatment with a complex of DDMC delivery system and sncRNAs.

Authors:  Oxana V Klimenko; Alexey Sidorov
Journal:  Noncoding RNA Res       Date:  2019-03-30

Review 8.  Sequencing the Biology of Entry: The Retroviral env Gene.

Authors:  Ronald Swanstrom; William D Graham; Shuntai Zhou
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

9.  Who is this man? Francis Peyton Rous.

Authors:  Prasanna Kumar; Frederick A Murphy
Journal:  Emerg Infect Dis       Date:  2013-04       Impact factor: 6.883

Review 10.  The Importance of Being Non-Defective: A Mini Review Dedicated to the Memory of Jan Svoboda.

Authors:  Peter K Vogt
Journal:  Viruses       Date:  2019-01-18       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.